Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.75 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979488 | 0.90 | PTGES (0.72) | PTGESEPHX2 | |
| SCHEMBL2804908 | 0.87 | PTGES (0.67) | PTGESCYSLTR1CYSLTR2PDE4APDE4B | |
| SCHEMBL976770 | 0.86 | PTGES (1.00) | PTGESCYSLTR1CYSLTR2PDE4APDE4B | |
| SCHEMBL13075603 | 0.85 | PTGES (0.55) | PTGESCYSLTR1CYSLTR2PDE4APDE4B | |
| SCHEMBL2806373 | 0.85 | PTGES (0.66) | PTGESCYSLTR1CYSLTR2PDE4APDE4B | |
| SCHEMBL979430 | 0.82 | PTGES (0.50) | PTGESCYSLTR1CYSLTR2 | |
| SCHEMBL2803224 | 0.82 | PTGES (0.67) | PTGESCYSLTR1CYSLTR2PDE4APDE4B | |
| SCHEMBL979144 | 0.82 | PTGES (0.81) | PTGESCYSLTR1CYSLTR2PLA2G4A | |
| SCHEMBL2801664 | 0.82 | PTGES (0.64) | PTGESCYSLTR1CYSLTR2PLA2G4AEPHX2 | |
| SCHEMBL2805700 | 0.80 | PTGES (0.69) | PTGESCYSLTR1CYSLTR2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | claimed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | claimed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | PTGES 9/4885CYSLTR1 132/4885CYSLTR2 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.